Portal de Periódicos da CAPES

A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome

2005; Wiley; Volume: 94; Issue: 6 Linguagem: Inglês

10.1111/j.1651-2227.2005.tb01984.x

1651-2227

Colleen Ann Malloy, Pamela Nicoski, Jonathan Muraskas,

Respiratory Support and Mechanisms

Abstract Aim: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS). Methods: Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO 2 ) requirement in the first 48 h after surfactant therapy. Results: 58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6±3.6 and 29.3±2.9 wk, with average birthweights of 1394±699 and 1408±534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO 2 requirement compared to those who received beractant ( p =0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) ( p =0.02). Conclusions: Infants with RDS treated with poractant had a lower FiO 2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO 2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.